Surmodics (SRDX) has entered into a definitive agreement to be acquired by GTCR, a private equity firm with investment expertise across healthcare and healthcare
technology. The affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million.
Surmodics' Board has unanimously approved the transaction and resolved to recommend that stockholders vote in favor of the transaction. Upon completion, Surmodics will be a
privately held company and its common stock will no longer be listed on The Nasdaq Stock Exchange.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com